Entering text into the input field will update the search result below

Galena Q3 revenues up 38%

Nov. 03, 2014 4:42 PM ETSELLAS Life Sciences Group, Inc. (SLS) StockBy: Douglas W. House, SA News Editor
  • Galena Biopharma (GALE -6.8%) Q3 results ($M): Revenues: 1.6 (+38.5%); Costs and Expenses: 14.8 (+83.9%); Operating Loss: (13.2) (-91.6%); Net Loss: (6.2) (+33.5%); Loss Per Share: (0.05) (+54.5%); Quick Assets: 24.6 (-48.4%).
  • NeuVax Phase 3 Present trial status: 533 of 700 patients treated.
  • 2014 Guidance: Abstral revenue: $8M - 10M.

Recommended For You

More Trending News

About SLS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SLS--
SELLAS Life Sciences Group, Inc.